These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 23341456)

  • 21. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.
    Jane EP; Premkumar DR; DiDomenico JD; Hu B; Cheng SY; Pollack IF
    Mol Cancer Ther; 2013 Mar; 12(3):326-38. PubMed ID: 23325792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells.
    Klymenko T; Brandenburg M; Morrow C; Dive C; Makin G
    Mol Cancer Ther; 2011 Dec; 10(12):2373-83. PubMed ID: 22006676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
    Rooswinkel RW; van de Kooij B; Verheij M; Borst J
    Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
    Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
    Song JH; Kandasamy K; Kraft AS
    J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.
    Coloff JL; Macintyre AN; Nichols AG; Liu T; Gallo CA; Plas DR; Rathmell JC
    Cancer Res; 2011 Aug; 71(15):5204-13. PubMed ID: 21670080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.
    Morales AA; Kurtoglu M; Matulis SM; Liu J; Siefker D; Gutman DM; Kaufman JL; Lee KP; Lonial S; Boise LH
    Blood; 2011 Aug; 118(5):1329-39. PubMed ID: 21659544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
    Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.
    Yang TM; Barbone D; Fennell DA; Broaddus VC
    Am J Respir Cell Mol Biol; 2009 Jul; 41(1):14-23. PubMed ID: 19097992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
    Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
    Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
    Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.
    Wang B; Ni Z; Dai X; Qin L; Li X; Xu L; Lian J; He F
    Mol Cancer; 2014 Apr; 13():98. PubMed ID: 24779770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
    Choudhary GS; Tat TT; Misra S; Hill BT; Smith MR; Almasan A; Mazumder S
    Oncotarget; 2015 Jul; 6(19):16912-25. PubMed ID: 26219338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.
    Olberding KE; Wang X; Zhu Y; Pan J; Rai SN; Li C
    Cancer Biol Ther; 2010 Nov; 10(9):918-29. PubMed ID: 20818182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
    Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY
    Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
    Chen S; Dai Y; Pei XY; Grant S
    Mol Cell Biol; 2009 Dec; 29(23):6149-69. PubMed ID: 19805519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
    Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
    Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.